Dossier assessment
Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of pulmonary arterial hypertension in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class II to III
Added benefit not proven
Project details
- Project no.
- A23-57
- Commission
- Commission awarded on 26.06.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Riociguat (CTEPH) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Riociguat (PAH) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Riociguat - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed